Pellikaan Karlijn, Snijders Fleur, Rosenberg Anna G W, Davidse Kirsten, van den Berg Sjoerd A A, Visser W Edward, van der Lely Aart J, de Graaff Laura C G
Department of Internal Medicine, Division of Endocrinology, Erasmus Medical Center, University Medical Centre Rotterdam, 3015 GD Rotterdam, The Netherlands.
Department of Internal Medicine, Division of Endocrinology, Center for Adults with Rare Genetic Syndromes, Erasmus Medical Center, University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands.
J Clin Med. 2021 Aug 25;10(17):3804. doi: 10.3390/jcm10173804.
Prader-Willi syndrome (PWS) is a complex genetic syndrome combining hypotonia, hyperphagia, a PWS-specific neurocognitive phenotype, and pituitary hormone deficiencies, including hypothyroidism. The low muscle mass associated with PWS causes a low energy expenditure due to a low basal metabolic rate. Combined with increased energy intake due to hyperphagia, this results in a high risk of obesity and associated cardiovascular disease. To reduce the high mortality in PWS (3% yearly), exercise is extremely important. As hypothyroidism can impair exercise tolerance, early detection is crucial. We performed a literature search for articles on hypothyroidism in PWS, measured thyroid hormone (TH) levels in 122 adults with PWS, and performed a medical file search for medication use. Hypothyroidism (low free thyroxin) was present in 17%, and often central in origin (80%). Triiodothyronine levels were lower in patients who used psychotropic drugs, while other TH levels were similar. One in six patients in our cohort of adults with PWS had hypothyroidism, which is more than in non-PWS adults (3%). We recommend yearly screening of free thyroxin and thyroid-stimulating hormone levels to avoid the negative effects of untreated hypothyroidism on basal metabolic rate, body mass index, and cardiovascular risk. Additionally, we recommend measuring TH concentrations 3-4 months after the start of growth hormone treatment.
普拉德-威利综合征(PWS)是一种复杂的遗传综合征,其特征包括肌张力减退、食欲亢进、特定的PWS神经认知表型以及垂体激素缺乏,其中包括甲状腺功能减退。与PWS相关的低肌肉量由于基础代谢率低而导致能量消耗减少。再加上食欲亢进导致能量摄入增加,这就造成了肥胖及相关心血管疾病的高风险。为降低PWS患者的高死亡率(每年3%),运动极为重要。由于甲状腺功能减退会损害运动耐量,早期检测至关重要。我们检索了关于PWS患者甲状腺功能减退的文献,测量了122名成年PWS患者的甲状腺激素(TH)水平,并查阅医疗档案以了解用药情况。甲状腺功能减退(游离甲状腺素水平低)的发生率为17%,且多为中枢性病因(80%)。使用精神药物的患者三碘甲状腺原氨酸水平较低,而其他TH水平相似。在我们的成年PWS患者队列中,六分之一的患者患有甲状腺功能减退,这一比例高于非PWS成年患者(3%)。我们建议每年筛查游离甲状腺素和促甲状腺激素水平,以避免未经治疗的甲状腺功能减退对基础代谢率、体重指数和心血管风险产生负面影响。此外,我们建议在生长激素治疗开始3 - 4个月后测量TH浓度。